Published by Global Banking & Finance Review®
Posted on February 26, 2025
1 min readLast updated: January 25, 2026
Syngenta acquires Novartis' genetic repository to enhance biologic crop protection, leasing facilities in Basel and hiring researchers.
FRANKFURT (Reuters) - Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologic crop protection.
In its statement, China-controlled Syngenta said that Novartis will retain exclusive rights to the repository for pharmaceutical use, without disclosing financial terms.
Under the deal, Syngenta will lease a fermentation pilot plant and science laboratories in Basel as well as hire a team of biomolecular chemistry researchers at Novartis.
Syngenta has been investing to develop organisms, natural molecules, plant extracts, and other bio-based materials to complement its chemical crop protection products.
(Reporting by Ludwig Burger, Editing by Miranda Murray)
The main topic is Syngenta's acquisition of a genetic repository from Novartis to enhance biologic crop protection.
The acquisition includes a repository of natural compounds and genetic strains, as well as leasing a fermentation pilot plant and science laboratories.
Novartis retains exclusive rights to the repository for pharmaceutical use.
Explore more articles in the Headlines category
